Import from '@/components/mdx'

Trulicity (Dulaglutide) for Adolescent Girls Ages 12 to 17: School, Sports, and Daily Life

What Is Trulicity and Why Is It Prescribed to Teen Girls?

Dulaglutide, sold as Trulicity, is a glucagon-like peptide-1 (GLP-1) receptor agonist injected once weekly. The FDA approved it for adults with type 2 diabetes in 2014 and extended that approval to children aged 10 and older in 2022, based on the AWARD-PEDS trial. It is not currently FDA-approved for weight loss in adolescents, though clinicians sometimes prescribe it off-label in teen girls with obesity and comorbidities such as PCOS or prediabetes.

GLP-1 receptors are present throughout the gut, brain, and pancreas. Dulaglutide slows gastric emptying, increases insulin secretion when blood sugar is high, suppresses glucagon, and reduces appetite. For teen girls specifically, these effects land on a body that is already navigating puberty-driven insulin resistance, menstrual cycle fluctuations, and rapid growth.

Puberty and Insulin Resistance in Girls

Girls typically enter puberty between ages 8 and 13. During Tanner stages II through IV, growth hormone surges reduce insulin sensitivity by roughly 30%, creating a window where type 2 diabetes risk climbs sharply, especially in girls with obesity or a family history of metabolic disease. Dulaglutide targets this insulin-resistance mechanism directly.

PCOS Overlap

Polycystic ovary syndrome affects an estimated 6 to 13% of adolescent girls, and insulin resistance sits at the center of its pathology. While dulaglutide is not approved specifically for PCOS, a prescribing clinician may discuss it as an adjunct in a teen who has both type 2 diabetes and features of PCOS. If your daughter or you are in this situation, ask specifically whether metformin, a GLP-1, or both are being recommended and what the evidence base is for each.

The AWARD-PEDS Trial: What the Evidence Actually Shows

The most relevant trial for adolescent girls is AWARD-PEDS (NCT02963766), a randomized, double-blind, placebo-controlled study published in the New England Journal of Medicine in 2022. Participants were aged 10 to 17 with type 2 diabetes inadequately controlled on diet, exercise, and metformin.

Key findings at 26 weeks:

• Dulaglutide 0.75 mg reduced HbA1c by 0.6 percentage points versus a 0.5-point increase in the placebo group, a difference of 1.1 percentage points.
• Dulaglutide 1.5 mg reduced HbA1c by 0.9 percentage points versus placebo.
• Nausea occurred in 13.8% of participants on 0.75 mg and 17.2% on 1.5 mg, compared with 3.4% on placebo.

The trial did not report outcomes by sex separately in enough detail to draw firm conclusions about girls versus boys, which is a genuine evidence gap. Most participants were female (approximately 60%), so the overall results likely reflect female physiology reasonably well, but sex-stratified subgroup data would be more useful. This is an area where WomanRx believes the field needs to do better.

A practical framework for reading AWARD-PEDS data as a teen girl or her parent: the 13 to 17% nausea rate is a real-world planning number. Roughly 1 in 6 to 1 in 7 teens on a therapeutic dose will experience nausea significant enough to note it to their study team. That does not mean it will be severe or last more than a few weeks, but it does mean you should have a plan for school days.

Dosing and Injection Logistics for School-Age Teens

Starting Dose and Titration

The approved starting dose for adolescents is 0.75 mg subcutaneously once weekly. Your prescriber may keep your teen on this dose if HbA1c targets are met or step up to 1.5 mg if more glycemic control is needed after at least 4 weeks. Unlike semaglutide (Ozempic/Wegovy), dulaglutide does not have an approved adolescent titration schedule above 1.5 mg, so the adult escalation pathway to 3 mg or 4.5 mg does not apply here.

Choosing Injection Day

The once-weekly schedule gives significant flexibility. The injection can be given any day of the week, at any time, with or without food. The dose day can also be moved by up to 3 days if needed, which matters for adolescents because:

• A teen may want to avoid injecting on the morning of a big exam (peak nausea tends to occur 24 to 48 hours post-injection).
• A competitive athlete may want to schedule the injection after a major game, not before.
• A school trip or camp can disrupt the usual routine; a 3-day shift keeps the teen protected without missing a dose.

If shifting the injection day, always leave at least 4 days between two consecutive doses.

Storage and School Logistics

Trulicity autoinjectors must be refrigerated at 36 to 46°F (2 to 8°C) but can be kept at room temperature up to 77°F (25°C) for up to 14 days. This means:

• The injector can travel to school in a regular lunch bag without a cold pack for a day.
• For longer trips, a small insulated pouch with an ice pack is adequate.
• Most schools allow a student to self-administer injectable medications with a signed medical authorization form from the prescriber and parent.

Work with the school nurse to complete the required medication authorization paperwork before the school year begins. This typically takes 1 to 3 weeks, so do not leave it to the first week of classes.

Managing Nausea and GI Side Effects at School

Nausea is the most new side effect for a teen girl at school. Here is what actually helps, based on clinical guidance and the prescribing information:

Timing the Injection to Minimize School-Day Nausea

Peak nausea from dulaglutide tends to occur in the first 1 to 3 days after injection and diminishes over the first 4 to 8 weeks. A practical strategy:

• Inject on Friday evening so the worst nausea falls on the weekend.
• Avoid injecting Sunday night if Monday is a test or presentation day.
• After 8 weeks, most teens find the nausea has reduced enough that injection day matters less.

Dietary Adjustments During the School Day

The cafeteria environment is not designed for someone managing GLP-1 side effects. Specific adjustments that help:

• Eat small amounts slowly. A teen on dulaglutide should aim for 5 to 6 small meals or snacks rather than 3 large ones, especially in the first 8 weeks.
• Avoid greasy cafeteria food on injection days 1 to 2. High-fat meals slow gastric emptying further, compounding the drug's own gastroparesis effect.
• Cold or room-temperature foods are often better tolerated than hot foods when nausea is present.
• Ginger chews or ginger tea have modest evidence for chemotherapy-induced nausea and are used anecdotally for GLP-1 nausea; there is no RCT in this specific population.

When to Leave Class

If a teen feels nauseated at school, she should know she has permission to go to the nurse's office to rest, sip water, and eat a small snack. This is not a reason to stop the medication. A clinical red flag that warrants calling the prescriber same-day is vomiting severe enough that she cannot keep liquids down for more than 6 hours.

Sports, Exercise, and Physical Education

Can Teen Girls on Trulicity Play Sports?

Yes. There is no contraindication to exercise on dulaglutide. Physical activity actually improves glycemic control synergistically with GLP-1 therapy by increasing muscle glucose uptake independently of insulin. Teen girls in sports should view the two as complementary, not competing.

Hypoglycemia Risk During Activity

Dulaglutide used alone does not cause hypoglycemia because its insulin-secreting effect is glucose-dependent. Blood sugar falls during exercise, but dulaglutide's mechanism turns off below euglycemia. If your teen is also on insulin or a sulfonylurea alongside dulaglutide, hypoglycemia risk during prolonged exercise is real and requires a plan with her diabetes care team.

Signs of hypoglycemia to know for PE class and sport:

• Shakiness, sweating, confusion, rapid heartbeat
• Blurry vision or difficulty concentrating mid-drill
• Unusual irritability that is not her baseline

Every teen on a sulfonylurea plus a GLP-1 should carry a fast-acting carbohydrate source (glucose tablets, juice box) during sport, per ADA Standards of Care 2024.

Dehydration and Electrolytes

Reduced food intake from appetite suppression, combined with sweat losses during sport, creates a meaningful dehydration risk. Teen girls are already prone to underestimating fluid needs during exercise. On training days, encourage at least:

• 17 to 20 oz of water 2 hours before activity
• 8 oz every 20 minutes during practice
• Replacement of sodium and potassium after sessions longer than 60 minutes (a sports drink, salted snack, or banana all work)

Severe vomiting from GI side effects plus dehydration from sport is the combination that can send a teen to an urgent care clinic. Preventing it is straightforward: do not schedule injections the morning before a long practice.

Talking to Coaches and Athletic Trainers

Your teen does not have to disclose her diagnosis or medication to coaches, but it helps to share a few practical facts:

• She may need to eat a small snack before or during practice.
• She may feel mildly nauseated on certain days; this is expected and temporary.
• If she is also on insulin or a sulfonylurea, the coach should know the signs of hypoglycemia and where she keeps her glucose source.

A brief, single-page written summary from her diabetes care team addressed to her athletic trainer is often the most efficient approach.

Menstrual Cycle Considerations for Teen Girls on Dulaglutide

This section exists because no competitor article for adolescent Trulicity mentions it. It matters.

How the Cycle Affects GI Tolerance

Progesterone in the luteal phase (roughly days 14 to 28 of a 28-day cycle) slows gastrointestinal motility on its own. Dulaglutide also slows gastric emptying. The two effects compound. In the week before menstruation, a teen on dulaglutide may notice that her usual nausea is worse, her appetite is lower, and bloating is more pronounced. This is physiological, not a sign that the drug has stopped working or that her dose needs to change.

Practical response: plan the injection toward the first half of the cycle (follicular phase, days 1 to 13) when progesterone is low, if injection-day timing flexibility exists.

Cycle Regularity and GLP-1 Therapy

GLP-1 receptor agonists do not directly suppress the hypothalamic-pituitary-ovarian axis. However, significant caloric restriction or rapid weight loss can suppress LH pulsatility and cause oligomenorrhea. If a teen on dulaglutide loses weight quickly and her periods become irregular or stop, her prescriber needs to know. This is not a reason to panic, but it is a reason to check in.

Period Pain and Nausea Overlap

Dysmenorrhea and dulaglutide-related nausea can overlap in timing if the injection falls close to menstruation. Ibuprofen (400 to 600 mg) is compatible with dulaglutide and can reduce prostaglandin-driven cramping without affecting glycemic control. Avoid taking ibuprofen on an empty stomach, which is more likely when appetite is suppressed by the drug.

Pregnancy, Contraception, and Lactation

Dulaglutide is contraindicated in pregnancy. This is not optional information for a sexually active adolescent.

Pregnancy Data

Animal studies showed dulaglutide caused fetal harm (reduced fetal weight, skeletal abnormalities) at doses producing exposures similar to the human clinical dose. Human pregnancy data are insufficient to establish safety, and the drug should be stopped as soon as pregnancy is confirmed or suspected. Because dulaglutide has a half-life of approximately 5 days, it clears the body within about 4 to 5 weeks after the last dose.

Any sexually active teen girl prescribed dulaglutide should be counseled about contraception before her first injection. Reliable options include combined hormonal contraceptives (pill, patch, ring), progestin-only methods, or long-acting reversible contraceptives (IUD, implant). The choice should account for her diabetes management, since combined oral contraceptives can modestly worsen insulin resistance, making progestin-only or non-hormonal methods worth discussing with her care team.

Lactation

Dulaglutide's lactation data in humans are absent from the prescribing label. It is present in rat milk. Because the drug is a large peptide, oral bioavailability to an infant would likely be negligible, but given the lack of human data and the teratogenicity signal in animals, most clinicians advise against use while breastfeeding. This is unlikely to be clinically relevant for most 12 to 17-year-olds, but it belongs in this article for completeness and for the older teen who may be postpartum.

Who This Is Right For and Who Should Pause

Teen Girls Who May Benefit Most

• Ages 12 to 17 with established type 2 diabetes not adequately controlled on metformin alone.
• Girls with obesity and significant insulin resistance, including those with features of PCOS.
• Teen athletes who would benefit from a non-hypoglycemia-causing agent to manage blood sugar during variable activity levels.
• Girls who have difficulty remembering daily medications; a once-weekly injection removes the daily pill burden.

Situations That Warrant Extra Discussion First

• A teen who is actively trying to conceive (this is rare at 12 to 17 but not impossible) or who is already pregnant.
• Girls with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, since GLP-1 agonists carry an FDA boxed warning for this risk in rodents (human relevance is uncertain but the warning stands).
• Teen girls with a history of pancreatitis, gastroparesis, or severe GI dysmotility.
• Those with eating disorder history, since appetite suppression in this population requires careful monitoring. Dulaglutide's effects on hunger and fullness could interact with restrictive eating patterns in ways that are not well studied. The ADA 2024 Standards of Care recommend screening for disordered eating in youth with type 2 diabetes before adding appetite-suppressing therapy.

Talking to Teachers, the School Nurse, and Administrators

Many teachers have never heard of dulaglutide. You do not need them to understand the pharmacology. You need them to understand three things:

1. Your teen has a medical condition managed with a weekly injection.
2. She may occasionally feel nauseated, need to eat a snack in class, or need to leave briefly.
3. The school nurse has a copy of her medication authorization form.

A brief meeting with the school nurse at the start of each academic year, with a written care plan from her diabetes team, covers most contingencies. The American Diabetes Association's Safe at School program provides template care plan documents and information on legal protections under Section 504 and IDEA for students with diabetes. If her school is not cooperating with reasonable accommodations, that program is a starting resource.

Practical Weekly Checklist for a Teen Girl on Trulicity

The following structure is designed to reduce missed doses and side-effect surprises across the school week.

Day of injection (recommend Thursday or Friday evening):

• Remove autoinjector from refrigerator 30 minutes before use.
• Inject into abdomen, outer thigh, or upper arm.
• Eat a small, low-fat dinner that evening.
• Note any redness, bruising, or lump at the injection site.

Day 1 to 2 post-injection:

• Eat small, frequent meals. Avoid greasy or heavy cafeteria food.
• Carry a ginger chew or a plain cracker pack in your backpack.
• Drink at least 64 oz of fluid, more on training days.

Day 3 to 7 post-injection:

• Side effects typically ease. Resume normal eating patterns.
• If nausea has not improved after 8 weeks on a stable dose, contact the prescriber.

Monthly:

• Track injection dates and any side effects in a simple notes app.
• Note cycle phase on injection day to identify patterns.
• Attend scheduled HbA1c and weight check appointments.